Dengue vaccine

U.S. Centers for Disease Control Guidance Includes EUROIMMUN Assay in its Two-Step Testing Algorithm for Dengue Virus

Retrieved on: 
Thursday, February 3, 2022
Biotechnology, Medical Devices, Infectious Diseases, Health, Pharmaceutical, Safety, Food, Government, YouTube, ELISA, Automation, Republic, Dengue vaccine, World, PKI, Twitter, Decision-making, ESG, NS1, Research, COVID-19, Instagram, PerkinElmer, CDC, Marshall Islands, Antibody, Fever Dream, Company, Public health, World Health Organization, Informatics, Science, Immunoglobulin G, Zika virus, NYSE, LinkedIn, MMWR, RNA, Solution, Vaccine, Zika fever, Facebook, American Samoa

Dengue disease is caused by four distinct, but closely related dengue viruses (DENV-14), which are part of the same group of vector-borne RNA viruses as the Zika virus.

Key Points: 
  • Dengue disease is caused by four distinct, but closely related dengue viruses (DENV-14), which are part of the same group of vector-borne RNA viruses as the Zika virus.
  • Antibodies formed against flaviviruses like dengue and Zika can cross-react and be detected by serological assays.
  • However, because eligibility for the Dengvaxia vaccine requires proof of prior dengue infection, an assay that can measure virus-specific antibodies for dengue, such as the EUROIMMUN Anti-Dengue Virus NS1 Type 1-4 ELISA, is needed.
  • The EUROIMMUN Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG) is based on recombinant virus-specific NS1 antigen of types 1-4.

Insights on the Dengue Vaccines Global Market to 2031 - Featuring Sanofi Pasteur, GlaxoSmithKline and VabioTech Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Health, Pharmaceutical, Medical specialties, Infectious diseases, Clinical medicine, Tropical diseases, Dengue fever, Vaccination, Vaccine, Virology, Dengue vaccine, Compound annual growth rate

The report provides revenue of the global dengue vaccines market for the period of 2017-2031, considering 2020 as the base year and 2031 as the forecast year.

Key Points: 
  • The report provides revenue of the global dengue vaccines market for the period of 2017-2031, considering 2020 as the base year and 2031 as the forecast year.
  • The report also provides the compound annual growth rate (CAGR %) of the global dengue vaccines market from 2021 to 2031.
  • These serve as valuable tools for existing market players as well as for entities interested in participating in the global dengue vaccines market.
  • Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global dengue vaccines market profiled in this report.

Worldwide Dengue Vaccine Industry to 2025 - Key Drivers, Challenges and Trends - ResearchAndMarkets.com

Retrieved on: 
Monday, June 21, 2021
Infectious diseases, Pharmaceutical, Health, Medical specialties, Infectious diseases, Clinical medicine, Dengue fever, Vaccines, Tropical diseases, Dengue vaccine, Vaccine

The publisher has been monitoring the dengue vaccine market and it is poised to grow by $132.90 million during 2021-2025, progressing at a CAGR of about 18% during the forecast period.

Key Points: 
  • The publisher has been monitoring the dengue vaccine market and it is poised to grow by $132.90 million during 2021-2025, progressing at a CAGR of about 18% during the forecast period.
  • This report on the dengue vaccine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The dengue vaccine market analysis includes the end-user segment and geographic landscape.
  • This study identifies the initiatives for dengue vaccine research and dengue immunization programs as one of the prime reasons driving the dengue vaccine market growth during the next few years.

Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results

Retrieved on: 
Saturday, May 22, 2021
Health, Infectious diseases, Other Health, Other Science, Research, Science, Pharmaceutical, Medical specialties, Dengue fever, Infectious diseases, Clinical medicine, Dengue vaccine, Vaccines, Dengue virus, Vaccine, COVID-19 vaccine, TAK-003, the Phase 3 TIDES (DEN-301) Trial, Dengue, Takeda Pharmaceutical Company Limited, TAK-003, THE PHASE 3 TIDES (DEN-301) TRIAL, DENGUE, TAKEDA PHARMACEUTICAL COMPANY LIMITED

\xe2\x80\x9cResults from the long-term analysis of Takeda\xe2\x80\x99s dengue vaccine candidate suggest that it could help with outbreak prevention, reduce rates of hospitalization and protect people from dengue regardless of their previous exposure.

Key Points: 
  • \xe2\x80\x9cResults from the long-term analysis of Takeda\xe2\x80\x99s dengue vaccine candidate suggest that it could help with outbreak prevention, reduce rates of hospitalization and protect people from dengue regardless of their previous exposure.
  • It is caused by any of four dengue virus serotypes, each of which can cause dengue fever or severe dengue.
  • Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial .
  • Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomized, placebo controlled, phase 3 trial.

Global Dengue Vaccines Disease Market Analysis Report 2021-2022: Average Probability a Product Advances from Phase III is 68.5%

Retrieved on: 
Wednesday, April 21, 2021
Infectious diseases, Medical specialties, Clinical medicine, Vaccines, Dengue fever, Dengue vaccine, Antiviral drug

Given that most dengue-endemic regions consist of low-income countries, they are unlikely to implement the necessary serostatus screening programs that would allow identification of individuals eligible to receive Dengvaxia.

Key Points: 
  • Given that most dengue-endemic regions consist of low-income countries, they are unlikely to implement the necessary serostatus screening programs that would allow identification of individuals eligible to receive Dengvaxia.
  • TV003/TV005 remains behind TAK-003 in development, with a Phase III trial in Brazil assessing the vaccine\'s safety and efficacy expected to be completed in H2 2021.
  • Exportation to other dengue-endemic markets could also pose a serious strategic threat to Takeda\'s TAK-003.\nThe overall likelihood of approval of a Phase I antiviral asset is 12.9%, and the average probability a product advances from Phase III is 68.5%.
  • Antiviral products, on average, take 8.4 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.\n'

Global Dengue Vaccines Disease Analysis Report 2021-2022: Approvals of TV003/TV005 and Domestic Vaccines will Lead to Considerable Competition - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 15, 2021
Infectious diseases, Pharmaceutical, Health, Medical specialties, Clinical medicine, Medicine, Vaccination, Virology, Vaccines, Dengue fever, Dengue vaccine, Vaccine, Attenuated vaccine, Antiviral drug, Merck & Co.

b'The "Disease Analysis: Dengue Vaccines" report has been added to ResearchAndMarkets.com\'s offering.\nThe dengue vaccines market is expected to expand rapidly following the anticipated launch of TAK-003 in 2021/22.\nThe pipeline remains active with two late-phase live-attenuated vaccines (LAVs), Takeda\'s TAK-003 and Merck & Co\'s TV003/TV005, in development in dengue-endemic regions.

Key Points: 
  • b'The "Disease Analysis: Dengue Vaccines" report has been added to ResearchAndMarkets.com\'s offering.\nThe dengue vaccines market is expected to expand rapidly following the anticipated launch of TAK-003 in 2021/22.\nThe pipeline remains active with two late-phase live-attenuated vaccines (LAVs), Takeda\'s TAK-003 and Merck & Co\'s TV003/TV005, in development in dengue-endemic regions.
  • Given that most dengue-endemic regions consist of low-income countries, they are unlikely to implement the necessary serostatus screening programs that would allow identification of individuals eligible to receive Dengvaxia.
  • TV003/TV005 remains behind TAK-003 in development, with a Phase III trial in Brazil assessing the vaccine\'s safety and efficacy expected to be completed in H2 2021.
  • Antiviral products, on average, take 8.4 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005792/en/\n'

V-Shield™ Face Mask Proven by University of Wisconsin to Protect Against SAR-CoV-2 and Influenza

Retrieved on: 
Wednesday, April 7, 2021
Medical specialties, Infectious diseases, Clinical medicine, Vaccines, Dengue fever, Dengue vaccine, Vaccine

These findings are the product of an exhaustive study led by Dr. Jorge Osorio.

Key Points: 
  • These findings are the product of an exhaustive study led by Dr. Jorge Osorio.
  • He previously co-founded Inviragen, a biotechnology company that created a Dengue vaccine that recently successfully completed phase 3 clinical trials.
  • Virustatic Shield Ltd. and University of Wisconsin are preparing this research for publication and peer review by the scientific community as they continue testing on further Viruferrin technology.
  • The V-Shield 360-degree Protective Face Mask is a non-medical face covering for use by the general public with the patented anti-viral protein coating, Viruferrin.

Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

Retrieved on: 
Thursday, March 25, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Dengue fever, Infectious diseases, Medical specialties, Clinical medicine, Dengue vaccine, Dengue virus, Dengue fever, TAK-003, the Phase 3 TIDES (DEN-301) Trial, Dengue, Takeda Pharmaceutical Company Limited

Submission of regulatory filings for our dengue vaccine candidate, TAK-003, marks an important development for people who are living in or traveling to communities burdened by the threat of dengue, said Derek Wallace, VP, Dengue Global Program Leader at Takeda.

Key Points: 
  • Submission of regulatory filings for our dengue vaccine candidate, TAK-003, marks an important development for people who are living in or traveling to communities burdened by the threat of dengue, said Derek Wallace, VP, Dengue Global Program Leader at Takeda.
  • Takeda is committed to working with regulatory authorities and recommending bodies to support evaluation of our submissions and achieve access for TAK-003.
  • Takeda also intends to submit regulatory filings in the United States, followed by additional countries in Asia and Latin America.
  • It is caused by any of four dengue virus serotypes, each of which can cause dengue fever or severe dengue.

KM Biologics Announces Phase I Clinical Study Results of a Live Attenuated Tetravalent Dengue Vaccine (KD-382)

Retrieved on: 
Thursday, March 25, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medical specialties, Infectious diseases, Clinical medicine, Dengue fever, Virology, Neglected tropical diseases, Tropical diseases, Vaccination, Dengue vaccine, Dengue virus, Mosquito-borne disease, Vaccine

KM Biologics Co., Ltd. (Headquarters: Kumamoto, Japan; CEO: Toshiaki Nagasato) announced the results of the Phase I clinical study (hereinafter the Study) of a live attenuated tetravalent vaccine, KD-382*1 (hereinafter, the KD-382 vaccine), to prevent dengue*2.

Key Points: 
  • KM Biologics Co., Ltd. (Headquarters: Kumamoto, Japan; CEO: Toshiaki Nagasato) announced the results of the Phase I clinical study (hereinafter the Study) of a live attenuated tetravalent vaccine, KD-382*1 (hereinafter, the KD-382 vaccine), to prevent dengue*2.
  • The results show that the KD-382 vaccine is safe and well-tolerated by healthy adults.
  • KD-382 is a live attenuated tetravalent dengue vaccine that is expected to be effective against all four serotypes with a single dose.
  • Dengue virus is a mosquito-borne virus belonging to the Flaviviridae family and causes dengue fever, dengue hemorrhagic fever, and dengue shock syndrome in humans.

Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine

Retrieved on: 
Monday, March 15, 2021
Health, Infectious diseases, Manufacturing, Other Manufacturing, Pharmaceutical, Biotechnology, Health sciences, Health care, Health, Medical research, COVID-19 vaccine, Novavax, Dengue vaccine, Vaccine, Takeda, Pharmaceutical industry, Takeda’s COVID-19 Efforts, Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced a mutual agreement with IDT Biologika GmbH (IDT), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takedas dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced a mutual agreement with IDT Biologika GmbH (IDT), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takedas dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • We are pleased to work with IDT to support Janssens efforts to make its COVID-19 vaccine available and accessible to as much of the world as possible, said Rajeev Venkayya, President, Global Vaccine Business Unit at Takeda.
  • Takeda will receive a manufacturing technology transfer from Novavax and will be responsible for the development and commercialization based on manufacturing capacity of over 250 million doses.
  • Takeda is well positioned to meet its commitments to support the public health needs associated with both COVID-19 and dengue.